ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
AstraZeneca
Origin Sciences
UMC Utrecht
National Taiwan University Hospital
AstraZeneca
A2 Biotherapeutics Inc.
University of Nebraska
Adela, Inc
Imperial College London
Memorial Sloan Kettering Cancer Center
Travera Inc
AstraZeneca
A2 Biotherapeutics Inc.
Tempus AI
Abramson Cancer Center at Penn Medicine
Royal Marsden NHS Foundation Trust
Labcorp Corporation of America Holdings, Inc
Singlera Genomics Inc.
University Health Network, Toronto
Travera Inc
DxTerity Diagnostics
University of Sydney
Beijing Friendship Hospital
Peking University Third Hospital
Namida Lab
MiRXES Pte Ltd
Wuhan Ammunition Life-tech Co., Ltd
Exact Sciences Corporation
Technische Universität Dresden
Assistance Publique - Hôpitaux de Paris
Weprom
Charite University, Berlin, Germany
University of Southern California
SpeciCare
Gary Onik MD
University of Zurich
Swiss Cancer Institute
CureOne
American College of Radiology Imaging Network
GlaxoSmithKline
Wake Forest University Health Sciences
GlaxoSmithKline
Amgen
M.D. Anderson Cancer Center
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC